AI-Designed Vaccine Successfully Tested in Human Trial.
Scientists at the University of Cambridge have successfully completed early human trials of a new artificial intelligence-designed vaccine called pEVAC-PS, marking a major breakthrough in medical technology and infectious disease prevention.
The vaccine was developed using advanced AI systems that analyzed global genomic data to identify shared characteristics across multiple viruses. This approach allowed researchers to design a broad-spectrum antigen capable of targeting a wide range of coronavirus-related strains.
Unlike traditional vaccines, pEVAC-PS was administered using a microfluid jet-like delivery device that injects the vaccine into the skin without a conventional needle. Researchers say this method could improve precision and patient comfort in future immunizations.
The clinical trial involved 39 healthy volunteers aged between 18 and 50. Participants were recruited from medical research centers in Southampton and Cambridge, where they received different dosage levels ranging from 0.2 mg to 1.2 mg.
The results showed that the vaccine was well tolerated, with no significant adverse side effects reported during the initial trial phase. Scientists confirmed that the study demonstrated both safety and early immune response potential.
The AI system behind the vaccine was trained to identify a common antigen structure shared among Sarbeco coronavirus family members, including SARS-CoV-2, SARS, and other related bat-origin coronaviruses. This could allow the vaccine to provide broader protection against future emerging variants.
Researchers believe this approach could revolutionize vaccine development by enabling faster design of treatments for viruses such as influenza, Ebola, and other high-risk pathogens.
Experts involved in the study say AI-driven vaccine design may significantly shorten development time and improve global preparedness for future pandemics.
